Ahmed Abdelhafez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ahmed Abdelhafez has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed Abdel-Wahab
Department of Cardiology Heart Center Leipzig at Leipzig University Leipzig Germany
6 shared publications Hans-Josef Feistritzer
Department of Structural Heart Disease/Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany
3 shared publications- Holger Thiele
Department of Cardiology Heart Center Leipzig at Leipzig University Leipzig Germany
3 shared publications Ines Richter
Department of Structural Heart Disease/Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany
3 shared publications- Johannes Rotta Detto Loria
Department of Cardiology Heart Center Leipzig at Leipzig University Leipzig Germany
3 shared publications Oliver Dumpies
Department of Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany
3 shared publications
Latest Publications
- 12 October 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (19) , 2677
REPLY
- Open Access
- 8 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (11) , 1393-1402
Impact of Leaflet Modification on the Occurrence of Hypoattenuated Leaflet Thickening After Valve-in-Valve Transcatheter Aortic Valve Replacement
- 8 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (11) , 1393-1402
Open AccessImpact of Leaflet Modification on the Occurrence of Hypoattenuated Leaflet Thickening After Valve-in-Valve Transcatheter Aortic Valve Replacement
- Open Access
- 8 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (11) , 1422-1431
Leaflet Splitting to Prevent TAVR-Induced Coronary Obstruction in Stented vs Stentless Surgical Bioprosthetic Valves
- 8 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (11) , 1422-1431
Open AccessLeaflet Splitting to Prevent TAVR-Induced Coronary Obstruction in Stented vs Stentless Surgical Bioprosthetic Valves
- Open Access
- 8 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (11) , 1516-1519
Commissural Misalignment–Mediated Sinus Sequestration Following Balloon-Augmented BASILICA During Redo-TAVR
- 8 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (11) , 1516-1519
Open AccessCommissural Misalignment–Mediated Sinus Sequestration Following Balloon-Augmented BASILICA During Redo-TAVR
- Open Access
- 8 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (11) , 1406-1419
CT-Based Risk Stratification of Coronary Obstruction During TAVR
- 8 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (11) , 1406-1419
Open AccessCT-Based Risk Stratification of Coronary Obstruction During TAVR
- 1 November 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 16 (11) , e013296
Redo Transcatheter Aortic Valve Implantation in the Lotus Mechanically Expanded Transcatheter Heart Valve: Bench-Top Analysis, Clinical Experience, and Procedural Guidance
BACKGROUND: Redo transcatheter aortic valve implantation (TAVI) is increasing as patients outlive their transcatheter heart valves (THVs) and present with bioprosthetic valve failure. The Lotus mechanically expanded THV has unique design characteristics, which have specific implications for Redo TAVI. METHODS: The design features of the Lotus valve and their relevance to Redo TAVI were reviewed. Bench-top analysis of Redo TAVI was performed using different contemporary THVs. Procedural and outcome data were obtained from 10 patients who had undergone Redo TAVI for Lotus bioprosthetic valve failure in 5 centers. Recommendations for performing Redo TAVI in Lotus are made, based on these findings. RESULTS: The Lotus leaflets extend from the frame inflow, with a Neoskirt of only 13 mm, hence a low risk of coronary obstruction during Redo TAVI. The Lotus frame posts prevent full apposition of the Redo prosthesis in the upper part of the frame, while implantation of the Redo THV above the Lotus inflow leads to inadequate apposition of the Lotus leaflets. Inflow-to-inflow positioning is therefore recommended for effective sealing and leaflet pinning. The Lotus locking mechanism prevents overexpansion of the frame, limiting Redo THV oversizing. Redo TAVI was favorable with SAPIEN 3, Evolut, and Navitor THVs on bench-top analysis but not with ACURATE Neo 2 due to the upper crowns and short stent preventing inflow-to-inflow deployment. Case review demonstrated satisfactory outcomes in 10 patients treated with Evolut (n=6), SAPIEN 3 (n=3), and Portico (n=1) valves, with no mortality, major morbidity, or coronary obstruction. Three patients had residual mean gradient ≥20 mm Hg, including 2 of 3 SAPIEN cases. Guidance on procedural planning, valve choice, sizing, and positioning is provided. CONCLUSIONS: Redo TAVI in Lotus requires an understanding of unique design characteristics, and adherence to key procedural recommendations, but can be safely and effectively performed with most contemporary valve types.
- 1 November 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 16 (11) , e013296
Redo Transcatheter Aortic Valve Implantation in the Lotus Mechanically Expanded Transcatheter Heart Valve: Bench-Top Analysis, Clinical Experience, and Procedural Guidance
BACKGROUND: Redo transcatheter aortic valve implantation (TAVI) is increasing as patients outlive their transcatheter heart valves (THVs) and present with bioprosthetic valve failure. The Lotus mechanically expanded THV has unique design characteristics, which have specific implications for Redo TAVI. METHODS: The design features of the Lotus valve and their relevance to Redo TAVI were reviewed. Bench-top analysis of Redo TAVI was performed using different contemporary THVs. Procedural and outcome data were obtained from 10 patients who had undergone Redo TAVI for Lotus bioprosthetic valve failure in 5 centers. Recommendations for performing Redo TAVI in Lotus are made, based on these findings. RESULTS: The Lotus leaflets extend from the frame inflow, with a Neoskirt of only 13 mm, hence a low risk of coronary obstruction during Redo TAVI. The Lotus frame posts prevent full apposition of the Redo prosthesis in the upper part of the frame, while implantation of the Redo THV above the Lotus inflow leads to inadequate apposition of the Lotus leaflets. Inflow-to-inflow positioning is therefore recommended for effective sealing and leaflet pinning. The Lotus locking mechanism prevents overexpansion of the frame, limiting Redo THV oversizing. Redo TAVI was favorable with SAPIEN 3, Evolut, and Navitor THVs on bench-top analysis but not with ACURATE Neo 2 due to the upper crowns and short stent preventing inflow-to-inflow deployment. Case review demonstrated satisfactory outcomes in 10 patients treated with Evolut (n=6), SAPIEN 3 (n=3), and Portico (n=1) valves, with no mortality, major morbidity, or coronary obstruction. Three patients had residual mean gradient ≥20 mm Hg, including 2 of 3 SAPIEN cases. Guidance on procedural planning, valve choice, sizing, and positioning is provided. CONCLUSIONS: Redo TAVI in Lotus requires an understanding of unique design characteristics, and adherence to key procedural recommendations, but can be safely and effectively performed with most contemporary valve types.
- Open Access
- 23 October 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 102 (7) , 1393-1400
Transcatheter aortic valve implantation in patients with anomalous origin of a coronary artery
Transcatheter aortic valve implantation (TAVI) has become a well‐established treatment option for elderly patients with symptomatic severe aortic stenosis. Coronary artery anomalies are an infrequent finding and there have only been few anecdotal reports of patients with coronary anomalies treated with TAVI. We here present a comprehensive overview of existing reports in addition to an own case series to facilitate better understanding of this potentially challenging clinical scenario.
- 23 October 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 102 (7) , 1393-1400
Open AccessTranscatheter aortic valve implantation in patients with anomalous origin of a coronary artery
Transcatheter aortic valve implantation (TAVI) has become a well‐established treatment option for elderly patients with symptomatic severe aortic stenosis. Coronary artery anomalies are an infrequent finding and there have only been few anecdotal reports of patients with coronary anomalies treated with TAVI. We here present a comprehensive overview of existing reports in addition to an own case series to facilitate better understanding of this potentially challenging clinical scenario.